Companies › Liquidia Technologies
1 active drug program in 4 registered trials: 3 Phase 3, 1 Phase 4; Cardiovascular; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Treprostinil (LIQ861) Prostanoid IP receptor agonist | PTGIR | Phase 4 | Pulmonary Arterial Hypertension (PAH); Primary Pulmonary Hypertension; Pulmonary Hypertension Due to Lung Disease (Disorder); Pulmonary Arterial Hypertension | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03992755 | Treprostinil (LIQ861) | Phase 3 | Primary Pulmonary Hypertension | Cardiovascular | May 2025 |
| NCT07759804 | Treprostinil (LIQ861) | Phase 4 | Pulmonary Arterial Hypertension (PAH) | Cardiovascular | May 2027 |
| NCT07285655 | Treprostinil (LIQ861) | Phase 3 | Pulmonary Hypertension Due to Lung Disease (Disorder) | Cardiovascular | Jul 2029 |
| NCT04691154 | Treprostinil (LIQ861) | Phase 3 | Pulmonary Arterial Hypertension | Cardiovascular | Mar 2031 |
Trust Bio-sonics EVD Pharmacy and Medical Company Pulmovant EBI Anti Sepsis Agitated Solutions
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.